In fact, a classification of tumours into 4 types based on the presence of PD‐L1 positivity and/or tumour‐infiltrating lymphocytes has been proposed.68, 69 In some tumours like NSCLC, oncogenes may be more important drivers of tumour PD‐L1 expression compared to other tumours, like melanoma, in which it seems more influenced by infiltrating immune cells.69 Furthermore, as reported by Lyford‐Pike et al, in head and neck squamous cell carcinoma, the expression of PD‐L1 may be driven by both oncogenic and adaptive immune resistance mechanisms in the same lesion.70 This evidence concerns the gene CD274 and non-small cell lung carcinoma.